Clinical trials: Overweight and Obesity
Obesity
Clinical Observation of Implementing the MedGem Into a Medical Specialty Practice
Due to common CVD diseases associated from obesity, medical providers are in a position to provide assistance. However, less than 10% of all patients receive any weight loss advice from physicians.
- Trial name
- NCT00489502
- Testing
- Brief Counseling, REE Assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Microlife
Pre-diabetes
Evaluation of Video On-Demand Programming to Prevent Type 2 Diabetes in Adults
Over the past 40 years, diabetes has increased dramatically in parallel with rapid increases in obesity.About 90 to 95% of persons with diabetes have type 2 diabetes, which begins when the body becomes resistant to the hormone…
- Trial name
- Project NOT ME (NCT01768546)
- Testing
- Virtual Diabetes Prevention Program, Interactive tracking and problem solving web portal
- Volunteers
- 306 people
- Sponsor
- UnitedHealth Group
Obesity
Gastric Electrical Stimulation (GES) for the Treatment of Obesity
The purpose of this feasibility study is to provide safety data on the implantable Exilis gastric electrical stimulation (GES) system, to individually adjust stimulation parameters to levels that are comfortable for implanted…
- Trial name
- GES (NCT01823705)
- Testing
- Exilis Implantable Gastric Electrical Stimulation (GES)
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 32 people
- Sponsor
- Medtronic Corporate Technologies and New Ventures
Overweight/Obesity
Clinical Study of IBI362 in Healthy Chinese Male Subjects
This is a study to evaluate the pharmacokinetic characteristics and safety of IBI362 lyophilized powder and IBI362 liquid formulation in healthy Chinese male subjects.
- Trial name
- NCT04773977
- Testing
- IBI362 liquid formulation, IBI362 lyophilized powder
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity
ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity
The primary objective is to assess the safety and tolerability of single and multiple oral doses of ERX1000 in obese subjects.
- Trial name
- NCT04890873
- Testing
- ERX1000
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- ERX Pharmaceuticals
Obesity
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide.
- Trial name
- NCT05671653
- Testing
- PF-07081532, Semaglutide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overweight, Obesity
Assessing Health-Related Quality of Life and Willingness to Pay for Weight Management in Asia-Pacific by Gender
The purpose of this survey is to collect information for scientific research and to identify the impact of overweight and obesity on health-related quality of life.
- Trial name
- ASPECT - APAC (NCT06260696)
- Testing
- No treatment is given
- Where
- United Arab Emirates
- Volunteers
- 3,000 people
- Sponsor
- Novo Nordisk A/S
Overweight or Obese Participants Without Diabetes
A Study to Evaluate Efficacy and Safety of BGM1812 Injection in Overweight or Obese Participants Without Diabetes
To evaluate the efficacy of BGM1812 injection compared with placebo in reducing body weight in overweight or obese participants without diabetes after 26 weeks of treatment.
- Trial name
- NCT07918625
- Testing
- BGM1812 injection / plcaebo
- Where
- China
- Volunteers
- 160 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Type 2 Diabetes, Overweight or Obesity
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT05814107
- Testing
- CT-996
- Where
- 2 sites in Australia, Mexico
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Carmot Australia First Pty Ltd
Knee Osteoarthritis, Obesity
A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)
The main purpose of the study is to evaluate the efficacy and safety of ecnoglutide injections versus placebo in obese participants with KOA.
- Trial name
- NCT07734311
- Testing
- Ecnoglutide Injection
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Healthy
A Study in Healthy Men to Test How BI 456906 is Processed in the Body
This trial is intended to examine the basic pharmacokinetics of BI 456906 and total [14C]-radioactivity, including mass balance, excretion pathways and metabolism following a single subcutaneous (SC) dose of BI 456906 (C-14) in…
- Trial name
- NCT05421338
- Testing
- BI 456906 (C-14)
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Weight Loss
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735…
- Trial name
- NCT06828055
- Testing
- VK2735
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity
A Short-Term Study to Examine the Effects of ATHX-105 Phosphate on Weight Loss and Safety
This primary purpose of this study is to determine if ATHX-105 phosphate causes weight loss over a 12-week period.
- Trial name
- NCT00735683
- Testing
- ATHX-105 phosphate
- Sponsor
- Healios K.K.
Obesity
Injection Site Pain Comparison of Excipient Solutions
The purpose of this study is to investigate different solutions used to inject drugs under the skin. The solutions used in the study do not contain the drugs they will be used for, but they do contain excipients, which are…
- Trial name
- NCT04482725
- Testing
- Trial product 1, Trial product 2, Trial product 3
- Where
- Netherlands
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
Evaluation of Orlistat as Adjuvant Treatment of Obesity in Adults
The purpose of this study is to evaluate efficacy of orlistat 60 mg as adjuvant treatment of Obesity in adults.
- Trial name
- NCT01755676
- Testing
- Orlistat 60 mg
- Where
- 5 sites in Brazil
- Volunteers
- 638 people
- Sponsor
- EMS
Morbid Obesity
Six-month Study to Compare the Effects of Volume- and Pressure-Guided Adjustments on Weight Loss and Satiety
The purpose of this protocol is to determine how band fill volumes that are based on intraband pressure readings can influence the comfortability of the band and to compare weight loss with this methodology to weight loss with…
- Trial name
- NCT00960843
- Testing
- Intraband pressure recording system, Conventional Adjustment
- Where
- 2 sites in Australia, Czechia
- Volunteers
- 51 people
- Sponsor
- Ethicon Endo-Surgery
Obesity, Overweight, T2DM (Type 2 Diabetes Mellitus)
Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function
This is an open-label, non-randomized study to assess how DA-302168S is absorbed, distributed, metabolized, and eliminated after a single oral dose.
- Trial name
- NCT07877038
- Testing
- DA-302168S
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.
Obesity, Overweight
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and…
- Trial name
- NCT01601704
- Testing
- NB32, PBO, Weight Management Program
- Where
- 224 sites in United States
- Volunteers
- 8,910 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity & Overweight, Weight Loss
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health…
- Conditions
- Obesity & Overweight, Weight Loss, Preventative Health, Body Weight
- Trial name
- FLOURISH (NCT07588984)
- Testing
- Noom Weight, Free Tier, Education-only control
- Where
- United States
- Volunteers
- 2,310 people
- Sponsor
- Noom Inc.
Obesity
MOTIVATE Weight Loss Study
The purpose of this study is to evaluate the impact of minor variations in Incisionless Operating Platform (IOP)procedural techniques on gastric emptying, hormone levels, satiety, and weight loss in the treatment of primary…
- Trial name
- MOTIVATE (NCT01679158)
- Testing
- Using The IOP system from USGI to place suture anchors
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- USGI Medical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.